Targeting ASK1 signaling in neurodegeneration: molecular insights and therapeutic promise
- PMID: 40702249
- DOI: 10.1007/s10495-025-02148-3
Targeting ASK1 signaling in neurodegeneration: molecular insights and therapeutic promise
Abstract
Apoptosis signal-regulating kinase 1 (ASK1), a redox-sensitive member of the mitogen-activated protein kinase kinase kinase (MAP3K) family, is a master regulator of neuronal apoptosis as well as neuroinflammation in neurodegenerative disorders (NDs). Under oxidative and endoplasmic reticulum stress conditions, ASK1 sets off a series of pathways, ultimately leading to impairment of cellular functions and the cell's demise. The comprehensive review focuses on the diverse contributions of ASK1 to neurodegeneration driven by Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS). Human and animal evidence links dysregulated ASK1 signaling is related to amyloid deposition, tau hyperphosphorylation, neuroinflammation, abnormal protein folding, and subsequent neurodegeneration. ASK1 plays a role in tau hyperphosphorylation and amyloid-beta-induced neurotoxicity in AD. ASK1-mediated apoptosis of dopaminergic neurons caused by oxidative stress and aggregation of α-synuclein contributes to PD. Furthermore, ASK1 activation is associated with motor neuron degeneration in ALS related to endoplasmic reticulum stress caused by mutant SOD1. Moreover, the pathogenesis of HD involves the activation of ASK1 by the cellular stress caused by mutant huntingtin protein. ASK1 signaling potentiates inflammatory signals in MS because it is involved in demyelination and neuronal injury. Nonetheless, obstacles persist such as developing brain-targeted therapies, reducing adverse systemic effects, and defining disease-stage-specific functions of ASK1. This review aims to comprehensively examine the role of ASK1 signaling in major NDs, discuss its upstream and downstream regulatory mechanisms, and evaluate the current and emerging therapeutic strategies targeting ASK1.
Keywords: ASK1 inhibitors; Microglia; Neurodegeneration; Neurodegenerative diseases; Neuroinflammation; Oxidative stress.
© 2025. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Conflict of interest statement
Declarations. Competing interests: The authors declare no competing interests. Informed consent: Not Applicable.
Similar articles
-
Dysbiosis and Neurodegeneration in ALS: Unraveling the Gut-Brain Axis.Neuromolecular Med. 2025 Jul 3;27(1):50. doi: 10.1007/s12017-025-08870-0. Neuromolecular Med. 2025. PMID: 40608189 Review.
-
Neuromodulatory role and therapeutic potential of N6-methyladenosine RNA methylation in neurodegenerative diseases.Neural Regen Res. 2025 Jul 5. doi: 10.4103/NRR.NRR-D-24-01648. Online ahead of print. Neural Regen Res. 2025. PMID: 40618260
-
Genomic ncRNAs regulating mitochondrial function in neurodegeneration: a neglected clue in the complex etiopathogenesis of multiple sclerosis.Cell Biosci. 2025 Jun 28;15(1):93. doi: 10.1186/s13578-025-01438-2. Cell Biosci. 2025. PMID: 40581642 Free PMC article.
-
C/EBPβ: A transcription factor associated with the irreversible progression of Alzheimer's disease.CNS Neurosci Ther. 2024 Apr;30(4):e14721. doi: 10.1111/cns.14721. CNS Neurosci Ther. 2024. PMID: 38644578 Free PMC article.
-
Unravelling the Proteinopathic Engagement of α-Synuclein, Tau, and Amyloid Beta in Parkinson's Disease: Mitochondrial Collapse as a Pivotal Driver of Neurodegeneration.Neurochem Res. 2025 Apr 16;50(3):145. doi: 10.1007/s11064-025-04399-7. Neurochem Res. 2025. PMID: 40240583 Review.
References
-
- Lamptey RNL, Chaulagain B, Trivedi R, Gothwal A, Layek B, Singh J (2022) A review of the common neurodegenerative disorders: current therapeutic approaches and the potential role of nanotherapeutics. Int J Mol Sci 23
-
- Gonzales MM, Garbarino VR, Pollet E, Palavicini JP, Kellogg DL Jr, Kraig E et al (2022) Biological aging processes underlying cognitive decline and neurodegenerative disease. J Clin Investig 132
-
- Khan G, Hussain MS, Khan Y, Fatima R, Ahmad S, Sultana A et al (2025) Ferroptosis and its contribution to cognitive impairment in alzheimer’s disease: mechanisms and therapeutic potential. Brain Res 1864:149776 - PubMed
-
- Wilson DM, Cookson MR, Van Den Bosch L, Zetterberg H, Holtzman DM, Dewachter I (2023) Hallmarks of neurodegenerative diseases. Cell 186:693–714 - PubMed
-
- Kampmann M (2024) Molecular and cellular mechanisms of selective vulnerability in neurodegenerative diseases. Nat Rev Neurosci 25:351–371 - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous